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ABSTRACT 
OBJECTIVES
To compare the effectiveness and safety of surgical 
interventions for women with stress urinary 
incontinence.
DESIGN
Systematic review and network meta-analysis.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Randomised controlled trials evaluating surgical 
interventions for the treatment of stress urinary 
incontinence in women.
METHODS
Identification of relevant randomised controlled 
trials from Cochrane reviews and the Cochrane 
Incontinence Specialised Register (searched May 
2017), which contains trials identified from the 
Cochrane Central Register of Controlled Trials 
(CENTRAL), Medline, Medline In-Process, Medline 
Epub Ahead of Print, CINAHL, ClinicalTrials.gov, 
and WHO ICTRP. The reference lists of relevant 
articles were also searched. Primary outcomes were 
“cure” and “improvement” at 12 months, analysed 
by means of network meta-analyses, with results 
presented as the surface under the cumulative 
ranking curve (SUCRA). Adverse events were 
analysed using pairwise meta-analyses. Risk of bias 
was assessed using the Cochrane risk of bias tool. 
The quality of evidence for network meta-analysis 
was assessed using the GRADE approach.
RESULTS
175 randomised controlled trials assessing a total 
of 21 598 women were included. Most studies had 
high or unclear risk across all risk of bias domains. 
Network meta-analyses were based on data from 105 
trials that reported cure and 120 trials that reported 
improvement of incontinence symptoms. Results 
showed that the interventions with highest cure rates 
were traditional sling, retropubic midurethral sling 
(MUS), open colposuspension, and transobturator 
MUS, with rankings of 89.4%, 89.1%, 76.7%, and 
64.1%, respectively. Compared with retropubic 
MUS, the odds ratio of cure for traditional sling 
was 1.06 (95% credible interval 0.62 to 1.85), for 
open colposuspension was 0.85 (0.54 to 1.33), 
and for transobtrurator MUS was 0.74 (0.59 to 
0.92). Women were also more likely to experience 
an improvement in their incontinence symptoms 
after receiving retropubic MUS or transobturator 
MUS compared with other surgical procedures. 
In particular, compared with retropubic MUS, the 
odds ratio of improvement for transobturator MUS 
was 0.76 (95% credible interval 0.59 to 0.98), for 
traditional sling was 0.69 (0.39 to 1.26), and for 
open colposuspension was 0.65 (0.41 to 1.02). 
Quality of evidence was moderate for retropubic MUS 
versus transobturator MUS and low or very low for 
retropubic MUS versus the other two interventions. 
Data on adverse events were available mainly 
for mesh procedures, indicating a higher rate of 
repeat surgery and groin pain but a lower rate of 
suprapubic pain, vascular complications, bladder 
or urethral perforation, and voiding difficulties after 
transobturator MUS compared with retropubic MUS. 
Data on adverse events for non-MUS procedures 
were sparse and showed wide confidence intervals. 
Long term data were limited.
CONCLUSIONS
Retropubic MUS, transobturator MUS, traditional 
sling, and open colposuspension are more 
effective than other procedures for stress urinary 
incontinence in the short to medium term. Data 
on long term effectiveness and adverse events 
are, however, limited, especially around the 
comparative adverse events profiles of MUS and 
non-MUS procedures. A better understanding 
of complications after surgery for stress urinary 
incontinence is imperative.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42016049339.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Many surgical procedures, including open colposuspension and midurethral 
slings, are available to treat stress urinary incontinence
A large number of randomised controlled trials and several systematic reviews of 
randomised controlled trials have been conducted in this clinical area
The current evidence base is, however, fractured, focusing on pairwise 
comparisons with a lack of comparative data for all surgical interventions, 
making it difficult to judge which intervention is most effective overall
WHAT THIS STUDY ADDS
This review found that retropubic midurethral sling, transobturator midurethral 
sling, traditional sling, and open colposuspension are more likely to be effective 
than other surgical procedures for the treatment of women with stress urinary 
incontinence
The current evidence from randomised controlled trials is insufficient to establish 
long term effectiveness and safety of surgical interventions for stress urinary 
incontinence
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Introduction
Stress urinary incontinence—the leakage of urine 
resulting from increased intra-abdominal pressure 
during effort or exertion—is a common and distressing 
symptom that affects 25-45% of women.1 Risk 
factors include previous pregnancy, vaginal delivery, 
obesity, and postmenopausal status.2-4 Stress urinary 
incontinence profoundly impairs quality of life and 
also imposes a financial burden on women and the 
healthcare system, although recent estimates are 
not available.5 6 Estimates from the financial year 
1999/2000 of the annual spending on stress urinary 
incontinence vary from £117m ($151m; €135m) for 
treatment costs incurred by the UK National Health 
Service7 to £818m for combined health, personal, and 
societal costs.8 A US study reported that women with 
stress urinary incontinence pay about $750 each year 
out of pocket for routine care (2006 national resource 
costs), have a clinically significant reduction in health 
related quality of life, and are willing to pay nearly 
$1400 each year for a cure.9 Although many women 
delay accessing care because of embarrassment,10 11 
a UK study has estimated that around 15% of women 
with stress urinary incontinence would seek help.12 
On presentation, care typically consists of initial 
recommendation to use conservative treatments (eg, 
pelvic floor muscle training) and advice on lifestyle 
changes such as weight loss.13 If this initial approach 
fails, the next step is to offer surgery to decrease leakage.
Surgical treatment for stress urinary incontinence 
has evolved over the past two decades, with each 
procedure developed to overcome the limitations of 
previous procedures.14 One of the earliest operations 
was anterior repair with urethral buttressing 
sutures. The high failure rate with this and another 
operation—bladder neck needle suspension—led 
to the development of open colposuspension, an 
open abdominal surgery to support the bladder neck 
and urethra with sutures. This approach was more 
effective than the other two procedures and for many 
years was the standard surgical treatment for stress 
urinary incontinence. However, it was also associated 
with a higher perioperative and postoperative 
morbidity and a longer recovery time than the 
previous options. Laparoscopic colposuspension—
developed to overcome some of the problems with 
open colposuspension—was reported to be slightly 
less effective than open surgery. The high morbidity, 
longer recovery, and learning curve associated with 
laparoscopic colposuspension led to the development 
of traditional suburethral sling approaches, where 
a biological or synthetic sling is placed under the 
urethra and the free ends secured in several ways. 
These interventions were supplanted by mid-urethral 
sling (MUS) surgery in the late 1990s; a new minimally 
invasive, day case surgery that enabled a narrow 
strip of synthetic mesh (sling) to be placed with no 
fixation necessary (tension-free). The procedure 
has been adapted to include retropubic MUS (one 
vaginal incision and two lower abdominal incisions), 
transobturator MUS (one vaginal incision and two 
groin or thigh incisions), and, in recent years, a “mini-
sling” procedure, with only one small vaginal incision 
(single incision sling). In the surgical treatment of 
stress urinary incontinence, MUS has become the most 
common procedure worldwide.15 16
Since the introduction of MUS for the treatment of 
stress urinary incontinence, the number of surgeries 
has increased substantially.17 A study using NHS 
England data has shown that the number of surgeries 
for stress urinary incontinence increased from 8458 
in 2000-01 to a peak of 13 219 in 2008-09, before 
decreasing to 11 845 in 2012.15 Similarly, a US study 
estimated a 27% increase in the rate of surgeries 
over a 10 year period (2000 to 2009),18 associated 
with a rapid adoption of MUS and a correspon-
ding decrease in invasive procedures such as open 
colposuspension.15  18 The lifetime risk of surgery for 
stress incontinence or pelvic organ prolapse in the US 
has reportedly increased from 11% in 199519-21 to 20% 
in 2011.21 22
The safety of mesh implants for stress urinary 
incontinence and pelvic organ prolapse has, however, 
come under scrutiny owing to reports of women 
experiencing severe complications.16 23 The growing 
international controversy around vaginal mesh has led 
to litigation against manufacturers worldwide, forcing 
withdrawal of some products.24 25 In the UK, the Scottish 
government initially recommended a suspension 
of vaginal mesh surgery in 201426 and then called 
for an immediate halt on its use in September 2018. 
Similarly, in July 2018 the NHS in England announced 
a national “pause” for vaginal mesh surgery until 
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enough evidence became available to support its use 
in clinical practice.27 Ireland followed suit at the same 
time.28 In all these restrictions, no distinction was 
made between mesh for prolapse repair and mesh for 
incontinence procedures.
The impact of the recent suspension on the numbers 
of women seeking help is currently unclear. It is 
possible that more invasive surgery could re-emerge as 
alternative surgical options to MUS. Women, healthcare 
professionals, and policy makers therefore should be 
aware of the relative effectiveness and adverse effects 
of the surgical options for stress urinary incontinence.
Cochrane Incontinence has published eight 
systematic reviews of randomised controlled trials 
evaluating nine surgical interventions for the 
treatment of stress urinary incontinence in women.29-36 
These reviews represent the most relevant body of 
evidence for assessing the effectiveness of the surgical 
interventions. The reviews are, however, comprised 
of sets of pairwise comparisons between alternative 
surgical approaches. Although the review is useful, the 
plethora of possible comparisons makes interpretation 
of current evidence by both women and healthcare 
professionals difficult.
This work is part of a broader National Institute 
for Health Research Health Technology Assessment 
funded project, including an economic evaluation and 
a discrete choice experiment.37 In this paper, we report 
the clinical effectiveness component, which aimed to 
bring together all relevant randomised controlled trial 
evidence from the existing Cochrane reviews and more 
recently published randomised controlled trials. These 
data are incorporated into a network meta-analysis 
comparing the clinical effectiveness of the surgical 
procedures for stress urinary incontinence. We also 
reviewed the same evidence base to identify adverse 
events and complications associated with each type of 
surgical intervention.
Evidence acquisition
Search strategy and selection criteria
The methods of this evidence synthesis were 
prespecified in a research protocol; prospectively 
registered in the PROSPERO database.
We identified relevant randomised controlled 
trials from eight existing Cochrane reviews,29-36 
two obtained through personal communication 
(traditional suburethral slings: L Saraswat, 2016; 
laparoscopic colposuspension: MI Omar, 2016), and 
we performed an additional literature search (8 June 
2017) of the Cochrane Incontinence Specialised 
Register,38 which contains trials identified from 
the Cochrane Central Register of Controlled Trials 
(CENTRAL), Medline, Medline In-Process, Medline 
Epub Ahead of Print, CINAHL, ClinicalTrials.gov, and 
WHO ICTRP. We also hand searched journals and 
conference proceedings and perused the reference 
lists of relevant articles. No restriction was applied to 
publication status, year, or language of reports. Details 
of the search methods are available elsewhere.37 One 
reviewer (SW) examined the titles and abstracts of 
studies identified by the literature searches. The same 
reviewer assessed the full text papers and conference 
abstracts for potentially relevant studies, and these 
were checked by another reviewer (MI or MS) using 
the following criteria for inclusion: randomised 
controlled trials or quasi-randomised controlled trials 
(eg, alternate allocation), women with stress urinary 
incontinence or mixed urinary incontinence with 
predominant symptoms of stress urinary incontinence 
(diagnosis as defined by trial investigators), and 
comparison of two or more surgical interventions. We 
grouped surgical interventions into nine categories: 
open retropubic colposuspension, retropubic MUS, 
transobturator MUS, single incision sling, traditional 
suburethral sling, laparoscopic colposuspension, 
bladder neck needle suspension, anterior vaginal 
repair, and urethral bulking agent treatment. Studies 
that compared a surgical intervention with a non-
surgical intervention were included if they contributed 
data to generate network plots of comparisons of inter-
ventions. We excluded studies comparing specific 
technical variations of the relevant surgical procedure 
(eg, inside-out versus outside-in transobturator MUS). 
Disagreements on study eligibility for inclusion were 
resolved by consensus or by an arbitrator.
Outcome measures
Primary outcomes were the number of women with 
cure, defined as resolution of incontinence symptoms, 
and the number of women with improvement, defined 
as any improvement in incontinence symptoms from 
baseline, including cure. As a variety of measures were 
used to define cure or improvement, we combined data 
based on a hierarchy of reported outcomes. For cure, 
women’s self report (subjective measure) was given 
priority if available, followed by a composite measure 
of self report and objective indicators, and then by 
pad tests and urodynamic investigations (objective 
measures). For improvement, women’s self report 
was preferred when available, followed by women’s 
satisfaction, pad tests, and urodynamic investigations. 
Cough stress tests and diaries were not considered 
reliable measures and were excluded. We considered 
assessments performed at 12 months or closest to 
12 months as well as longer term assessments when 
available. We excluded studies if they only reported 
assessments within two weeks post-surgery.
Secondary outcomes were the number of women 
having repeated surgery for incontinence symptoms, 
adverse events, length of hospital stay, and operation 
time during the study period as reported by the trial 
investigators.
Data extraction and assessment of risk of bias
Cochrane reviews provided outcome data from 
individual randomised controlled trials, study cha-
racteristics, and findings of risk of bias assessment. 
We cross checked the primary outcome data (cure and 
improvement) against primary trial reports, whereas 
all other data, including adverse events, were extracted 
verbatim from the Cochrane reviews. One reviewer (MI 
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or MS) extracted data from new studies identified by 
the literature searches, and another reviewer (MI or 
MS) independently verified these against primary trial 
reports for accuracy and completeness, with risk of bias 
assessed using the Cochrane risk of bias tool.39 Authors 
of Cochrane reviews attempted to contact investigators 
of primary studies to obtain key missing data; this 
was not required for the new studies identified by the 
updated literature searches.
Data synthesis
For the assessment of primary outcomes (cure and 
improvement of symptoms), we conducted a network 
meta-analysis and combined direct evidence from head-
to-head comparisons and indirect comparisons, within 
a bayesian framework. The network meta-analysis was 
run in WinBUGS software (version 1.4.3),40 and further 
analysis was undertaken using Stata version 14.41 
Appendix 1 details the WinBUGS codes. Comparative 
effectiveness between interventions is reported as 
the median of posterior distribution of the odds ratio 
and the 95% credible intervals. Convergence was 
assessed using Brooks-Gelman-Rubin, trace, and 
autocorrelation plots. We also estimated the ranking 
probabilities of the different surgical treatments for 
cure and improvement using the surface under the 
cumulative ranking curves (SUCRA), which gives 
probabilities of each intervention being ranked the 
best (ie, having the highest proportion of women 
cured or improved). Consistency between the direct 
and indirect evidence was assessed by comparing 
the individual data point’s posterior mean deviance 
contributions for the consistency and inconsistency 
model and node splitting analysis.42
We included eight surgical procedures in the network 
meta-analysis. Urethral bulking agent treatment was 
excluded, as no trials were available that compared 
bulking agents with other surgical interventions. 
Pelvic floor muscle training was included to enable 
indirect comparisons. Trials were excluded if they 
reported 100% events in all arms (three43-45 from 
the cure dataset and four43-46 from the improvement 
dataset), as they provided no evidence for the network 
meta-analysis.
The primary and secondary outcomes were 
summarised using direct comparison meta-analysis 
on pairs of interventions for which there was at 
least one trial. A random effects model was used to 
account for variability in reporting and timing of 
outcome measures. Effect sizes are reported as odds 
ratios with 95% confidence intervals for dichotomous 
outcomes, and as standardised mean difference with 
95% confidence intervals for continuous outcomes. 
Heterogeneity was assessed using the I2 statistic.47 
Analyses were performed using Stata (version 14).41
Quality of the evidence for cure and improvement 
was assessed using the GRADE approach for network 
meta-analysis48 by one reviewer (MIO) and replicated 
by a second reviewer (MI). GRADE considers five 
criteria, including study design (judged according 
to the Cochrane risk of bias tool), inconsistency, 
imprecision, indirectness, and publication bias, and 
has four levels of evidence: high, moderate, low, and 
very low.48
We initially planned to analyse data according to 
relevant subgroups (ie, urodynamic or symptom based 
diagnosis of stress urinary incontinence, previous anti-
incontinence surgery, co-existing vaginal prolapse, 
and concomitant prolapse surgery). This was not 
feasible, however, because most trials did not provide 
information on these characteristics.
Patient and public involvement
This evidence synthesis directly involved two patient 
representatives. One patient representative (IM) acti-
vely contributed to the design (as an advisor for the 
grant application), conduct (including attendance at 
project and advisory group meetings), interpretation, 
and reporting of findings of this evidence synthesis. 
She is also included as co-author of this manuscript. 
Another patient representative (SB) was involved 
as a member of the advisory group for this project. 
Our work has also been shared with the National 
Institute for Health and Care Excellence to support the 
development of relevant guidelines. Other components 
of this project had a greater involvement of patients 
and it is planned to disseminate the results further 
through companion academic papers and directly to 
relevant health organisations.
Results
Characteristics of included studies
Data from 175 studies were included in the review; 
of those, 147 were from the Cochrane reviews and 28 
from the additional searches. Figure 1 shows the study 
selection flowchart (PRISMA).
The included studies involved 21 598 women and 
reported 21 treatment comparisons (table 1). Most 
involved MUS (retropubic or transobturator) as part 
of the interventions (97 studies). The most common 
intervention comparisons were transobturator MUS 
compared with retropubic MUS (58 studies) or 
compared with single incision slings (39 studies). 
This was followed by retropubic MUS versus open 
colposuspension (13 studies), open colposuspension 
versus laparoscopic colposuspension (12 studies), 
retropubic MUS versus traditional sling (9 studies), 
and retropubic MUS versus single incision slings 
(9 studies). For other comparisons, the number of 
available studies was small.
The included studies were published between 1978 
and 2016. Reflecting the incremental development 
of surgical treatment for stress urinary incontinence, 
newer studies (those published after 2000) tended 
to include MUS as one of the study arms. Similarly, 
the 28 newly identified studies also focused on MUS 
(retropubic or transobturator) versus single incision 
sling (20 studies) or the comparison of two MUS 
surgeries (retropubic versus transobturator MUS, 4 
studies). Thus, data for older procedures such as open 
colposuspension and traditional slings were derived 
from relatively older studies.
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Sample sizes were generally small (median 91 
participants per trial, range 15-655). Most studies 
(134/175, 76%) also had a short duration of follow-
up (median 12 months, range 1-126 months), with 
only 41 studies (23%) having a mean follow-up of 
three years or longer. Forty three studies (25%) were 
published only in abstract form.
Most of the included studies had high or unclear 
risk of bias across all risk of bias domains (table 2), 
but most notably for allocation concealment (selection 
bias). Blinding of participants and staff was not feasible 
owing to the nature of the intervention (surgery); 
inevitably limiting protection against performance and 
detection bias in most studies.
Effectiveness results: cure or improvement
Overall, 105 trials were available for the analysis of 
cure and 120 trials for the analysis of improvement. 
Figure 2 shows the network diagrams for cure and 
improvement.
Table 3 shows the results for direct (pairwise 
meta-analyses) and indirect comparisons (network 
meta-analysis) and the quality of evidence for cure of 
incontinence symptoms. The results of the network 
meta-analysis showed that traditional sling and 
retropubic MUS were more likely to be effective for curing 
(resolving) the symptoms of stress urinary incontinence, 
followed by open colposuspension and transobturator 
MUS (eg, compared with retropubic MUS, the odds ratio 
for traditional sling was 1.06 (95% credible interval 
0.62 to 1.85), quality of evidence: very low; for open 
colposuspension was 0.85 (0.54 to 1.33), quality of 
evidence: low; for transobturator MUS was 0.74 (0.59 
to 0.92), quality of evidence: moderate). The data for 
traditional sling and open colposuspension, however, 
were from only six studies; the 95% credible intervals 
around the estimates of effect were wide, and the overall 
quality of evidence was judged to be very low. The data 
for transobturator MUS were from 36 studies, and the 
quality of evidence was judged to be moderate.
Additional records retrieved by searching
the Cochrane Incontinence Group
Specialised Register were screened
Reports of 166 studies were identified
in the existing Cochrane reviews and screened
for relevance to ESTER
443
Reports of 147 included studies
406
Potentially relevant records were identified
and the full text retrieved
216
Reports of 175 studies were used in qualitative synthesis. Included in pairwise analyses if data were available
566
Studies that provided data for the network meta-analysis
120
Reports of 147 Cochrane included studies
were included in ESTER
502
Reports of 28 studies
64
591
Records excluded
375
Reports of 17 studies excluded
Wrong study design
Wrong study comparison
Wrong study population
5
9
3
35
Reports of 35 studies excluded
Wrong study design
Wrong study comparison
Wrong study population
Ongoing studies
Studies awaiting classification 
4
6
2
23
2
51
Additional reports of studies already
included in Cochrane reviews
and included in ESTER
100
Fig 1 | PRISMA flowchart of study selection
Table 1 | Number of included studies by treatment comparison
Control group Intervention group
Total No 
randomised
No of 
studies
No of studies 
from updated 
search
Retropubic MUS Transobturator MUS 8876 58 4
Retropubic MUS Open colposuspension 1240 13 0
Retropubic MUS Laparoscopic colposuspension 651 8 0
Retropubic MUS Traditional sling 868 9 0
Retropubic MUS Single incision sling 1092 9 3
Retropubic MUS Anterior repair 53 1 0
Transobturator MUS Open colposuspension 272 4 0
Transobturator MUS Laparoscopic colposuspension 35 1 0
Transobturator MUS Traditional sling 141 3 1
Transobturator MUS Single incision sling 4612 39 17
Transobturator MUS Anterior repair 120 2 1
Transobturator MUS Pelvic floor muscle training 460 1 1
Open colposuspension Laparoscopic colposuspension 1402 12 0
Open colposuspension Traditional sling 922 7 0
Open colposuspension Bladder neck needle suspension 639 7 0
Open colposuspension Anterior repair 690 8 0
Open colposuspension Pelvic floor muscle training 45 1 0
Traditional sling Single incision sling 72 1 1
Traditional sling Urethral injection therapy 45 1 0
Traditional sling Bladder neck needle suspension 20 1 0
Bladder neck needle 
suspension
Anterior repair 346 3 0
MUS=mid-urethral sling.
Study numbers do not add up to 175, as three arm trials are shown as pairwise comparisons.
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Table 4 shows the results for the direct (pairwise 
meta-analyses) and indirect comparisons (network 
meta-analysis) and the quality of evidence for the 
number of women who experienced an improvement 
in incontinence symptoms. Retropubic MUS was, 
on average, more effective than the other surgical 
interventions (median odds ratio <1.0). In particular, 
transobturator MUS, traditional sling, and open 
colposuspension had the highest median odds 
ratios for improvement against retropubic MUS (eg, 
compared with retropubic MUS, the odds ratio for 
transobturator MUS was 0.76 (95% credible interval 
0.59 to 0.98), quality of evidence: moderate; for 
traditional sling was 0.69 (0.39 to 1.26), quality of 
evidence: low; for open colposuspension was 0.65 
(0.41 to 1.02), quality of evidence: low), although the 
95% credible intervals around the estimates of effect 
for traditional sling and open colposuspension were 
wide. The quality of evidence for traditional sling and 
open colposuspension was judged to be low, whereas 
the quality of evidence for transobturator MUS was 
judged to be moderate.
The network meta-analysis for cure showed no 
evidence of inconsistency (see appendix 2). With 
regard to improvement there was evidence of incon-
sistency for pelvic floor muscle training compared 
with transobturator MUS and for traditional sling 
and pelvic floor muscle training compared with open 
colposuspension suggesting that the direct and indirect 
evidence were not in agreement (see appendix 2).
The SUCRA results showed that the interventions 
with the best probability of achieving the highest cure 
rates (fig 3) were traditional sling, retropubic MUS, 
open colposuspension, and transobturator MUS, with 
an average probability of 89.4%, 89.1%, 76.7%, and 
64.1%, respectively. For improvement (fig 4), the same 
four interventions were most likely to be the most 
effective, with an average probability of 97%, 76.1%, 
67.7%, and 63.8%, for retropubic MUS, transobturator 
MUS, traditional sling, and open colposuspension, 
respectively. All the other surgical interventions in the 
model had less than 50% probability of being in the 
top rank for both cure and improvement.
Secondary outcomes
Limited data were available for the assessment of 
secondary outcomes. In particular, meta-analyses 
of adverse events were hampered by the dearth of 
available data and the lack of common outcome 
definitions across individual trials and Cochrane 
reviews. We summarise the results of meta-analyses 
when data were reported by more than five studies 
and for those procedures that were most likely to be 
most effective based on the results of the network 
Table 2 | Summary of risk of bias assessment in included studies. Values are numbers (percentages) unless stated 
otherwise
Assessment item
Risk level No of studies 
assessedLow Unclear High
Random sequence generation (selection bias) 85 (49) 80 (46) 10 (6) 175
Allocation concealment (selection bias) 49 (28) 116 (66) 10 (6) 175
Blinding of participants and staff (performance bias) 8 (5) 123 (73) 37 (22) 168
Blinding of outcome assessment (detection bias): all outcomes 20 (15) 107 (81) 5 (4) 132
Blinding of outcome assessment (detection bias): patient reported outcomes 4 (11) 17 (47) 15 (42) 36
Blinding of outcome assessment (detection bias): clinician measured outcomes 8 (22) 20 (56) 8 (22) 36
Blinding (performance bias and detection bias) 1 (14) 6 (86) 0 (0) 7
Incomplete outcome data (attrition bias): all outcomes 54 (39) 76 (55) 9 (6) 139
Incomplete outcome data (attrition bias): patient reported outcomes 18 (50) 16 (44) 2 (6) 36
Incomplete outcome data (attrition bias): clinician measured outcomes 21 (58) 13 (36) 2 (6) 36
Selective reporting (reporting bias) 24 (65) 7 (19) 6 (16) 37
Other bias 0 (0) 82 (100) 0 (0) 82
Reflecting different publication dates of Cochrane reviews, different versions of Cochrane risk of bias tool were used. Risk of bias domains assessed were 
not consistent across Cochrane reviews included in this evidence synthesis.
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Fig 2 | Network plot for number of women showing cure (top panel) and improvement 
(bottom panel) of stress urinary incontinence symptoms. Circle size reflects number of 
women and line width reflects number of direct comparisons
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meta-analysis (fig 5). Appendix 3 shows the full meta-
analysis results for all included studies.
Repeat surgery for incontinence symptoms—rates 
of repeat surgeries were higher after transobturator 
MUS than after retropubic MUS at 12 months and 
more than 60 months, but the pooled analyses 
showed wide confidence intervals and considerable 
uncertainty around the estimates of effect (12 months, 
21/585 (3.6%) v 14/641 (2.2%), odds ratio 1.37 (95% 
confidence interval 0.55 to 3.46); more than 60 months, 
40/422 (9.4%) v 7/438 (1.5%), 4.06 (0.80 to 20.74)).
Major vascular complications—major vascular 
complications (as defined by the authors of Cochrane 
reviews) occurred less often after transobturator MUS 
than after retropubic MUS (10/2008 (0.5%) v 47/1966 
(2.4%), odds ratio 0.36 (0.21 to 0.64)).
Bladder or urethral perforation—rates of bladder or 
urethral perforation were generally higher with retropubic 
MUS compared with transobturator MUS (5/3161 (0.2%) 
v 157/3171 (5.0%), odds ratio 0.15 (0.09 to 0.24)), open 
colposuspension (5/338 (1.5%) v 28/362 (7.7%), 0.23 
(0.10 to 0.55)), and traditional sling (16/305 (5.2%) v 
28/276 (10.1%), 0.50 (0.28 to 0.98)).
De novo symptoms of urgency or urgency 
incontinence—the incidence of de novo urgency 
and urgency incontinence was similar between 
transobturator MUS and retropubic MUS (172/2264 
(7.6%) v 183/2321 (9.5%), odds ratio 0.93 (0.74 to 
1.17)). The results for the comparisons between open 
colposuspension and retropubic MUS (28/249 (11%) 
v 22/287 (8%), 1.49 (0.81 to 2.75)) and between 
single incision sling and transobturator MUS (63/665 
(9.5%) v 55/597 (9.2%), 0.98 (0.66 to 1.46)) did not 
favour either treatment and showed wide confidence 
intervals.
Voiding difficulties, including urinary retention—
voiding difficulties were less common with 
transobturator MUS than with retropubic MUS 
(116/3110 (3.7%) v 234/3109 (7.5%), odds ratio 
0.51 (0.40 to 0.64)). The summary estimates for open 
colposuspension versus retropubic MUS (29/374 
(7.8%) v 31/413 (7.5%), 0.87 (0.41 to 1.82)) and 
traditional sling versus retropubic MUS (40/259 
(15.4%) v 26/255 (10.2%), 1.46 (0.84 to 2.53)) did not 
favour one intervention over another and confidence 
intervals were wide.
Table 3 | Results for number of women with cure of stress urinary incontinence symptoms
Intervention 1 Intervention 2
Direct evidence Network meta-analysis
GRADE quality of evidenceNo of trials Odds ratio (95% CI) Odds ratio (95% Crl)
Transobturator MUS Retropubic MUS 36* 0.83 (0.71 to 0.97) 0.74 (0.59 to 0.92) Moderate
Open colposuspension Retropubic MUS 6* 0.95 (0.68 to 1.32) 0.85 (0.54 to 1.33) Low
Laparoscopic colposuspension Retropubic MUS 2 0.40 (0.11 to 1.45) 0.58 (0.31 to 1.05) Low
Traditional sling Retropubic MUS 6* 0.87 (0.58 to 1.29) 1.06 (0.62 to 1.85) Very low
Single incision Retropubic MUS 6* 0.42 (0.20 to 0.87) 0.50 (0.36 to 0.70) Low
Bladder neck needle suspension Retropubic MUS 0.34 (0.15 to 0.75) Low
Anterior repair Retropubic MUS 0.22 (0.10 to 0.45) Very low
Pelvic floor muscle training Retropubic MUS 0.12 (0.04 to 0.32) Low
Open colposuspension Transobturator MUS 1 0.90 (0.30 to 2.69) 1.16 (0.72 to 1.86) Low
Laparoscopic colposuspension Transobturator MUS 0.79 (0.42 to 1.46) Low
Traditional sling Transobturator MUS 1 2.00 (0.17 to 23.96) 1.44 (0.81 to 2.62) Very low
Single incision Transobturator MUS 21* 0.74 (0.54 to 1.00) 0.68 (0.51 to 0.91) Low
Bladder neck needle suspension Transobturator MUS 0.46 (0.21 to 1.02) Very low
Anterior repair Transobturator MUS 1 0.50 (0.15 to 1.62) 0.30 (0.14 to 0.62) Very low
Pelvic floor muscle training Transobturator MUS 1 0.20 (0.12 to 0.33) 0.16 (0.06 to 0.43) Low
Laparoscopic colposuspension Open colposuspension 9 0.74 (0.43 to 1.30) 0.68 (0.42 to 1.08) Low
Traditional sling Open colposuspension 3* 2.47 (0.73 to 8.40) 1.24 (0.66 to 2.45) Very low
Single incision Open colposuspension 0.59 (0.34 to 1.01) Low
Bladder neck needle suspension Open colposuspension 3* 0.41 (0.25 to 0.68) 0.40 (0.20 to 0.78) Low
Anterior repair Open colposuspension 3* 0.20 (0.07 to 0.60) 0.26 (0.14 to 0.48) Very low
Pelvic floor muscle training Open colposuspension 1 0.08 (0.01 to 0.51) 0.14 (0.05 to 0.39) Low
Traditional sling Laparoscopic colposuspension 1.83 (0.86 to 4.04) Very low
Single incision Laparoscopic colposuspension 0.87 (0.44 to 1.70) Low
Bladder neck needle suspension Laparoscopic colposuspension 0.59 (0.26 to 1.33) Very low
Anterior repair Laparoscopic colposuspension 0.38 (0.18 to 0.82) Very low
Pelvic floor muscle training Laparoscopic colposuspension 0.21 (0.07 to 0.63)
Single incision Traditional sling 0.47 (0.25 to 0.88) Very low
Bladder neck needle Traditional sling 1 1.00 (0.05 to 18.57) 0.32 (0.13 to 0.79) Very low
Anterior repair Traditional sling 0.21 (0.09 to 0.49) Very low
Pelvic floor muscle training Traditional sling 0.11 (0.04 to 0.34) Very low
Bladder neck needle suspension Single incision 0.67 (0.29 to 1.56)
Anterior repair Single incision 0.44 (0.20 to 0.96) Very low
Pelvic floor muscle training Single incision 0.24 (0.08 to 0.65) Low
Anterior repair Bladder neck needle suspension 1* 0.92 (0.55 to 1.55) 0.65 (0.30 to 1.36) Very low
Pelvic floor muscle training Bladder neck needle suspension 0.35 (0.10 to 1.17) Low
Pelvic floor muscle training Anterior repair 0.55 (0.17 to 1.77) Very low
MUS=mid-urethral sling.
*These analyses are also informed by three arm trials, including one comparing retropubic MUS, transobturator MUS, and single incision, one comparing retropubic MUS, open colposuspension, 
and traditional sling, and two comparing open colposuspension, bladder neck needle, and anterior repair.
An odds ratio >1 favours the first treatment—ie, more events (cure) occur. An odds ratio <1 favours the second treatment—ie, fewer events.
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Tape/mesh extrusion or exposure—the rate of 
tape/mesh erosion or extrusion appeared similar 
between transobturator MUS and retropubic MUS 
(53/2225 (2.4%) v 48/2298 (2.1%), odds ratio 
1.10 (0.70 to 1.70)), although confidence intervals 
were wide. The comparison of single incision sling 
versus transobturator MUS (19/399 (4.8%) v 13/354 
(3.7%), 1.23 (0.57 to 2.68)) did not favour either 
treatment and showed wide confidence intervals. 
The rate of exposure to tape or mesh was higher after 
single incision compared with transobturator MUS, 
but the summary estimate showed wide confidence 
intervals (25/494 (5.1%) v 11/463 (2.4%), 1.74 
(0.59 to 5.07)).
Pain—transobturator MUS was associated with a 
higher rate of groin pain compared with retropubic 
MUS (116/1833 (6.3%) v 24/1798 (1.3%), odds 
ratio 3.80 (2.45 to 5.89)), but with a lower rate of 
suprapubic pain (8/687 (1.2%) v 27/681 (4.0%), 
0.37 (0.17 to 0.84)). The rate of postoperative pain 
was higher after retropubic MUS than after single 
incision sling (176/916 (19.2%) v 64/946 (6.8%), 
0.21 (0.12 to 0.39)). The rate of unspecified pain 
was higher after transobturator MUS than after single 
incision sling (17/328 (5.2%) v 4/412 (1.0%), 0.24 
(0.06 to 0.92)).
Urinary tract infections—the rate of urinary tract 
infection was similar between single incision and 
transobturator MUS (36/544 (6.6%) v 26/447 (5.8%), 
odds ratio 1.11 (0.63 to 1.96)), although there was 
uncertainty around the summary estimate of effect.
Perioperative complications—perioperative compli-
cations were defined in different ways by the authors 
of Cochrane reviews and could include vascular 
events, bladder perforation, urinary tract infection, 
or pain, as well as other unspecified events. Results 
showed some degree of uncertainty for transobturator 
MUS versus retropubic MUS (127/1084 (11.7%) v 
150/1153 (13.0%), odds ratio 0.81 (0.55 to 1.19)) and 
open colposuspension versus retropubic MUS (97/338 
(29%) v 88/363 (24%), 1.19 (0.68 to 2.08)), and did 
not favour one treatment over the other.
Discussion
Using network meta-analyses we found that retropubic 
MUS, transobturator MUS, traditional sling, and open 
Table 4 | Results for number of women with improvement of stress urinary incontinence symptoms
Treatment 1 Treatment 2
Direct evidence Network meta-analysis GRADE quality  
of evidenceNo of trials Odds ratio (95% CI) Odds ratio (95% Crl)
Transobturator MUS Retropubic MUS 40* 0.86 (0.70 to 1.06) 0.76 (0.59 to 0.98) Moderate
Open colposuspension Retropubic MUS 6* 0.83 (0.55 to 1.24) 0.65 (0.41 to 1.02) Low
Laparoscopic colposuspension Retropubic MUS 4 0.49 (0.18 to 1.35) 0.52 (0.29 to 0.91) Low
Traditional sling Retropubic MUS 6* 0.62 (0.38 to 1.02) 0.69 (0.39 to 1.26) Low
Single incision Retropubic MUS 6* 0.42 (0.20 to 0.89) 0.50 (0.35 to 0.71) Moderate
Bladder neck needle suspension Retropubic MUS 0.25 (0.11 to 0.58) Low
Anterior repair Retropubic MUS 0.18 (0.08 to 0.39) Very low
Pelvic floor muscle training Retropubic MUS 0.43 (0.14 to 1.37) Low
Open colposuspension Transobturator MUS 1 0.90 (0.30 to 2.69) 0.85 (0.52 to 1.41) Low
Laparoscopic colpo Transobturator MUS 0.69 (0.37 to 1.26) Low
Traditional sling Transobturator MUS 1 2.00 (0.17 to 23.96) 0.91 (0.49 to 1.72) Very low
Single incision Transobturator MUS 28* 0.74 (0.57 to 0.96) 0.66 (0.49 to 0.89) Moderate
Bladder neck needle suspension Transobturator MUS 0.33 (0.14 to 0.79) Very low
Anterior repair Transobturator MUS 1 1.00 (0.26 to 3.89) 0.24 (0.10 to 0.53) Very low
Pelvic floor muscle training Transobturator MUS 1 0.18 (0.10 to 0.33) 0.56 (0.19 to 1.78) Low
Laparoscopic colposuspension Open colposuspension 9 0.93 (0.58 to 1.48) 0.81 (0.49 to 1.31) Low
Traditional sling Open colposuspension 3* 2.47 (0.73 to 8.40) 1.07 (0.54 to 2.15) Low
Single incision Open colposuspension 0.78 (0.44 to 1.36) Low
Bladder neck needle suspension Open colposuspension 3* 0.38 (0.22 to 0.63) 0.38 (0.18 to 0.81) Low
Anterior repair Open colposuspension 3* 0.20 (0.07 to 0.60) 0.28 (0.14 to 0.55) Very low
Pelvic floor muscle training Open colposuspension 1 8.87 (1.66 to 47.25) 0.66 (0.21 to 2.16) Low
Traditional sling Laparoscopic colposuspension 1.32 (0.62 to 2.98) Low
Single incision Laparoscopic colposuspension 0.97 (0.50 to 1.87) Low
Bladder neck needle suspension Laparoscopic colposuspension 0.47 (0.20 to 1.17) Very low
Anterior repair Laparoscopic colposuspension 0.34 (0.15 to 0.79) Very low
Pelvic floor muscle training Laparoscopic colposuspension 0.82 (0.25 to 2.88) Very low
Single incision Traditional sling 1 1.92 (0.65 to 5.64) 0.73 (0.37 to 1.39) Low
Bladder neck needle suspension Traditional sling 1 1.00 (0.05 to 18.57) 0.36 (0.13 to 0.95) Very low
Anterior repair Traditional sling 0.26 (0.10 to 0.65) Very low
Pelvic floor muscle training Traditional sling 0.62 (0.18 to 2.18) Very low
Bladder neck needle suspension Single incision 0.49 (0.20 to 1.24) Very low
Anterior repair Single incision 0.36 (0.15 to 0.82) Very low
Pelvic floor muscle training Single incision 0.84 (0.28 to 2.78) Low
Anterior repair Bladder neck needle suspension 1* 0.92 (0.55 to 1.55) 0.72 (0.31 to 1.63) Very low
Pelvic floor muscle training Bladder neck needle suspension 1.72 (0.45 to 6.89) Low
Pelvic floor muscle training Anterior repair 2.38 (0.65 to 9.30) Very low
MUS=mid-urethral slings.
*These analyses are also informed by two three arm trials comparing retropubic MUS, transobturator MUS, and single incision.
An odds ratio >1 favours the first treatment—ie, more events (improvement) occur. An odds ratio <1 favours the second treatment—ie, fewer events.
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colposuspension are the surgical interventions likely 
to be most effective in terms of cure of stress urinary 
incontinence at 12 months or closest to 12 months. 
Similarly, for improvement of incontinence symptoms, 
the same four interventions were likely to be the most 
effective.
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Fig 5 | Repeat surgery for stress urinary incontinence, adverse events, and resource use (only events reported by >5 studies). *Effect estimate is 
standardised mean difference. MUS=midurethral sling
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The safety profile of these procedures showed 
that transobturator MUS had a higher rate of repeat 
procedures and a higher occurrence of groin pain 
than retropubic MUS. Conversely, retropubic MUS was 
associated with a higher rate of suprapubic pain, as 
well as a higher rate of major vascular complications, 
bladder or urethral perforation, and voiding difficulties 
than transobturator MUS. The rate of tape or mesh 
erosion or extrusion was similar between the two 
procedures. The rate of postoperative pain was higher 
after retropubic MUS than after single incision sling, 
whereas the rate of unspecified pain was higher after 
transobturator MUS than after single incision sling.
Retropubic MUS had higher rates of bladder 
perforation compared with open colposuspension and 
traditional slings. Available data showed no evidence 
that retropubic MUS was better or worse than open 
colposuspension and traditional slings in terms of 
de novo urgency or urgency incontinence, voiding 
difficulties, and complications, although confidence 
intervals were wide, indicating considerable uncertainty. 
Few studies (<5 studies) reported other intervention 
comparisons and therefore data were insufficient to 
draw any meaningful conclusions about relative safety.
Overall completeness and applicability of evidence
Overall, the quality of evidence for the primary 
outcomes (cure and improvement) was moderate 
for transobturator MUS versus retropubic MUS or 
transobturator MUS versus single incision, which were 
assessed by most of the included studies. The other 
comparisons had a limited number of studies and 
quality of evidence was judged to be low or very low. 
The evidence level was downgraded mainly for high or 
unclear risk of bias and imprecision of effect estimates.
The available evidence predominantly relates to 
comparisons involving retropubic MUS, transobturator 
MUS, and single incision sling. Randomised 
controlled trials evaluating these mesh procedures 
were generally carried out in recent years, whereas 
comparative evidence for previous mainstream 
procedures was limited and tended to rely on older 
studies. Indeed, our searches identified no new trials 
for open or laparoscopic colposuspension compared 
with traditional slings or MUS. Compared with 
recent trials on the use of mesh procedures for stress 
urinary incontinence, older publications referring to 
traditional procedures tended to be of poorer reporting 
quality, which could have contributed to lower the 
evidence level for traditional procedures.
Data for the assessment of complications were 
sparse for all surgical procedures included in this 
study, particularly over the long term. There was 
considerable uncertainty around the estimates of 
effect, reflecting that in most cases the sample size was 
small, the event rate was low, and the study period was 
relatively short.
Strength and limitations in relation to other studies
The current debate on mesh surgery encompasses 
the treatment of both stress urinary incontinence 
and pelvic organ prolapse. A statement issued by the 
US Food and Drug Administration49 and the opinion 
expressed by the European Commission’s Scientific 
Committee on Emerging and Newly Identified 
Health Risks (SCENIHR)50 acknowledge that mesh 
associated morbidity is higher when treating pelvic 
organ prolapse, which uses a greater amount of mesh 
compared with treating stress urinary incontinence. 
These statements also accept that MUS surgery for stress 
urinary incontinence is effective and safe in studies 
with up to one year of follow-up but acknowledge 
the lack of long term data. Single incision slings have 
since been removed from the market in Australia51 and 
New Zealand,52 but this does not affect MUS for the 
treatment of stress urinary incontinence.
The rate of long term adverse events for MUS has 
been investigated in recent cohort studies. A large 
retrospective cohort study in England published 
in 2017 investigated the rate of complications of 
vaginal mesh procedures (including retropubic and 
transobturator MUS) for the treatment of stress urinary 
incontinence in more than 92 000 women over a 
period of eight years. The study estimated that 9.8% 
of women experienced peri-procedural complications, 
within 30 days or five years, and 5.9% were readmitted 
at least once for a further mesh procedure within five 
years of the index procedure.16
Another large observational study published in 
2017,23 as part of a Scottish independent review,26 
used routinely reported Scottish hospital inpatient 
data for more than 16 000 women between April 
1997 and March 2016. The findings showed that MUS 
procedures had a lower risk of immediate complications 
compared with open colposuspension (4%, 2%, and 
8% for retropubic MUS, transobturator MUS, and 
open colposuspension, respectively). Compared with 
open colposuspension, MUS surgery had a similar 
risk of readmission for later complications (10%, 9%, 
11%, respectively) and repeat surgery (4%, 5%, 6%, 
respectively) up to five years after the index surgery.23 
Infections and procedure related problems were the 
most common immediate and later complications after 
surgery. For procedures involving mesh, further surgery 
to remove the mesh was another later complication. 
Based on these findings, the Scottish independent 
review supports the use of mesh procedures for stress 
urinary incontinence but considers existing research 
evidence to be insufficient for safety and performance 
over the long term.
The NHS England Mesh Oversight Group report 
published in July 2017 reached a similar conclusion; 
that mesh procedures for the treatment of stress 
urinary incontinence are a safe option but evidence 
was insufficient to determine the extent of long term 
complications.53 The Mesh Oversight Group made 
several recommendations to ensure better quality 
of care. These include improvements to surgical 
practice and training, raising awareness of possible 
postoperative complications, and offering quicker and 
improved access to clinical expertise for women with 
postoperative complications.53
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Such observations are in line with the present 
study based on published randomised controlled 
trials. Although our findings show the effectiveness 
of MUS surgery for stress urinary incontinence to 
be comparable or superior to traditional surgeries 
in terms of cure and improvement, evidence is 
insufficient to assess long term safety. In addition, 
comparative data on adverse events available for 
non-mesh procedures for stress urinary incontinence 
are limited. This raises the question as to whether 
previous gold standard procedures could and 
should be considered as valid surgical alternatives, 
if MUS were no longer an option for women with 
stress urinary incontinence. Our findings are thus in 
keeping with the recommendations by the Scottish 
and English national inquiries, which stressed the 
importance of better reporting of adverse events and 
better hospital statistics coding procedures to have a 
more complete picture of the level and seriousness of 
complications after surgery.26 53 Previous systematic 
reviews have also highlighted this gap, and it is 
incumbent on future research to ensure that data on 
adverse events are properly assessed, collected, and 
analysed.
Strength and limitations of this study
To our knowledge, the current evidence synthesis 
is the first, comprehensive attempt to estimate the 
clinical effects and safety across all available surgical 
interventions for the treatment of women with stress 
urinary incontinence based on published clinical 
trials evidence. In particular, the strength of our study 
includes comprehensive coverage of all published 
randomised controlled trials on available surgery for 
stress urinary incontinence, and application of current 
best practice for undertaking systematic reviews. The 
network meta-analysis enabled comparison of any pair 
of surgical procedures under consideration, including 
those that were not directly compared in clinical trials. 
This greatly enhances the usefulness of the findings 
to patients, health professionals, and policy makers. 
Our multidisciplinary research team comprised 
clinicians, health service researchers, methodologists, 
statisticians, and patient representatives, who all 
contributed to the design and conduct of this evidence 
synthesis.
One limitation of this study was the lack of 
information on the severity of stress urinary 
incontinence in the included studies. The applicability 
of findings to women with varying degrees of 
severity is therefore uncertain. Heterogeneity of 
trial methodology among included studies, and, in 
particular, a lack of standard outcome measures, 
also restricted our ability to synthesise evidence. For 
example, type and definition of complications reported 
were not consistent across Cochrane reviews. We did 
not investigate the effects of specific variations in the 
use of the relevant surgical techniques (eg, inside-out 
versus outside-in transobturator sling insertion), or 
types of mesh material, as this was beyond the scope 
of this evidence synthesis. Another limitation of the 
current evidence base is that data on adverse events 
are collected as part of randomised controlled trials. It 
is recognised that such trials, which tend to be limited 
in size and duration, might not be the most appropriate 
study design to identify long term adverse effects, 
and particularly rare complications.54 Although two 
reviewers independently extracted outcome data and 
risk of bias in the published Cochrane reviews, data 
extraction and the risk of bias assessment of the 28 new 
studies identified from the update literature searches 
were undertaken by one reviewer and verified by a 
second reviewer against the original trial reports. This 
was a pragmatic decision owing to time constraints.
Our literature search was conducted in May 2017. 
We conducted an updated search in November 2018 
and identified an additional nine new studies that 
appeared to meet our inclusion criteria. Of these, only 
three small studies (<70 participants) include non-
MUS procedures (open colposuspension, bladder neck 
needle suspension, and anterior repair), whereas the 
other studies focus on mesh procedures (MUS or single 
incision slings). Given the relatively large number of 
randomised controlled trials covering MUS or single 
incision slings already included in the present study, 
we believed that inclusion of these new studies would 
not substantially change the network meta-analysis 
results or overall findings and conclusions.
Implications for practice and research
The current main uncertainty relates to the long 
term effectiveness and safety of surgical procedures 
for the treatment of stress urinary incontinence. As 
with previous reviews, this study highlights the need 
for further research that pays attention to adverse 
events that might not be common but could have an 
important adverse impact on women’s quality of life. 
Given our findings that MUS procedures are among the 
most effective surgical interventions for stress urinary 
incontinence, further research must identify which 
complications arise from the device itself (including 
type of mesh material used), insertion technique, 
or whole procedure. Training of surgeons and their 
ongoing surgical throughput may also need assessment. 
This would provide women with the necessary, broad 
range of evidence to help them understand the benefits 
and harms associated with the device and guide their 
choice of surgery. The assessment of long term safety 
and performance of mesh and non-mesh procedures 
would ideally require a large multicentre trial with 
an extended follow-up period (ie, a minimum of 
five years and possibly longer). A more realistic, less 
expensive, option would be to promote awareness 
of later complications associated with mesh among 
health professionals, as well as more precise reporting 
and recording of complications in national databases 
and registries to generate uniform and comprehensive 
data on surgery for stress urinary incontinence. 
Recently, the UK Royal College of Obstetricians and 
Gynaecologists welcomed the idea of a mandatory 
register to record outcomes in all women treated with 
vaginal mesh to properly monitor the adverse effects of 
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these implants and have a better understanding of how 
women are affected.55 It has also been suggested that 
a publicly accessible registry of licensed mesh devices 
with details of the marketing authorisation and linked 
evidence would provide useful information on the 
characteristics and performance of these devices.56 57
Another challenge in the current clinical practice 
is the lack of standardised data collection and the 
absence of a core outcome set for evaluation of surgery 
for stress urinary incontinence. This affects primary 
research and limits aggregation of data from primary 
studies for evidence synthesis. It is incumbent on 
stakeholders, incontinence related organisations, and 
researchers to develop core outcome sets and adverse 
events profile associated with surgery for stress urinary 
incontinence that are relevant to women, which will 
aid high quality, multicentre research.
Conclusions
In the short to medium term (12 months), retropubic 
MUS, transobturator MUS, traditional sling, and 
open colposuspension seem to be more effective 
than other surgical procedures for the treatment of 
stress urinary incontinence in women, although the 
quality of evidence was moderate at best and low or 
very low for most comparisons. Nevertheless, the 
comparative safety profile of these surgical procedures 
is still unclear. Evidence was also insufficient to assess 
the long term effectiveness and safety of surgical 
treatments. There is a clear need to address the current 
uncertainty around adverse events after surgery for 
stress urinary incontinence. Careful consideration of 
alternative surgical options and a better understanding 
of their associated risks and harms is a key requirement 
before opting for alternative, potentially less effective, 
non-MUS procedures.
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